Rocket Pharmaceuticals, Inc. Shareholders' Equity
Rocket Pharmaceuticals, Inc. (RCKT) had Shareholders' Equity of $368.83 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Parent $368.83M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $238.04M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $277.22M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $313.67M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $368.83M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $238.04M 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $277.22M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $313.67M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $354.21M 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $412.14M 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $463.23M 10-Q · filed 2026-08-10 | |
| 2024-09-30 | $329.77M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $384.63M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $441.50M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $492.57M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $541.09M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $402.97M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $458.88M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $489.69M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $367.31M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $387.70M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $417.62M 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $454.72M 10-K · filed 2025-02-27 | |
| 2021-09-30 | $485.66M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $489.44M 10-Q · filed 2022-11-04 | |
| 2021-03-31 | $480.00M 10-Q · filed 2022-11-04 | |
| 2020-12-31 | $503.52M 10-K · filed 2024-02-27 | |
| 2020-09-30 | $241.84M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $266.52M 10-Q · filed 2021-11-05 | |
| 2020-03-31 | $286.05M 10-Q · filed 2021-11-05 | |
| 2019-12-31 | $307.30M 10-K · filed 2023-02-28 | |
| 2019-09-30 | $231.92M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $248.50M 10-Q · filed 2020-11-06 | |
| 2019-03-31 | $177.08M 10-Q · filed 2020-11-06 | |
| 2018-12-31 | $194.04M 10-K · filed 2022-02-28 | |
| 2018-09-30 | $143.62M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $157.08M 10-Q · filed 2019-11-08 | |
| 2018-03-31 | $170.15M 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $15.52M 10-K · filed 2021-03-01 | $47.76M 10-K · filed 2018-03-07 |
| 2017-09-30 | $51.08M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $57.53M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $63.26M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $8.37M 10-K · filed 2019-03-08 | $73.17M 10-K · filed 2017-03-16 |
| 2016-09-30 | $85.05M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $95.44M 10-Q · filed 2016-08-10 | |
| 2016-03-31 | $99.24M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $15.54M 10-K · filed 2019-03-08 | $108.81M 10-K · filed 2016-03-23 |
| 2015-09-30 | $116.47M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $31.72M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $33.95M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | -$51.56M 10-K · filed 2017-03-16 | |
| 2013-12-31 | -$38.90M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |